IGC Pharma, Inc. (IGC)
- Previous Close
0.5109 - Open
0.5250 - Bid 0.5013 x 1000
- Ask 0.5199 x 4000
- Day's Range
0.5000 - 0.5210 - 52 Week Range
0.2500 - 0.9100 - Volume
197,915 - Avg. Volume
1,010,373 - Market Cap (intraday)
34.308M - Beta (5Y Monthly) 1.77
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2600 - Earnings Date Jul 10, 2024 - Jul 15, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.25
IGC Pharma, Inc., a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer's disease, dysmenorrhea, premenstrual syndrome, and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease comprising IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63 that is in pre-clinical development. It also markets Holief, a wellness brand that targets women experiencing premenstrual syndrome and menstrual cramps. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.
igcpharma.comRecent News: IGC
Performance Overview: IGC
Trailing total returns as of 5/7/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IGC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IGC
Valuation Measures
Market Cap
34.13M
Enterprise Value
33.13M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
23.55
Price/Book (mrq)
3.77
Enterprise Value/Revenue
27.25
Enterprise Value/EBITDA
-3.00
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-44.01%
Return on Equity (ttm)
-103.36%
Revenue (ttm)
1.22M
Net Income Avi to Common (ttm)
-14.14M
Diluted EPS (ttm)
-0.2600
Balance Sheet and Cash Flow
Total Cash (mrq)
1.38M
Total Debt/Equity (mrq)
4.20%
Levered Free Cash Flow (ttm)
-1.91M